Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

NCT ID: NCT03990883

Last Updated: 2025-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 295 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-04
• Study Completion Date: 2022-02-15

Brief Summary

Clinical Investigation to demonstrate the effectiveness and safety of Princess Filler Lidocaine in the correction of moderate to severe nasolabial folds

Detailed Description

Clinical Investigation to assess the effectiveness of "Princess Filler Lidocaine" in reducing the severity of nasolabial folds compared to "Juvederm Ultra XC", based on the independent blinded evaluating investigator live assessment using the Nasolabial Folds Severity Rating Scale (NLF-SRS) at Week 24 after initial treatment and relative to Baseline assessments

Conditions

Dermatological Non-Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment of device 1 on left side

Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF

Group Type: OTHER

Princess Filler Lidocaine

Intervention Type: DEVICE

correction of nasolabial folds

Treatment of device 1 on right side

Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF

Group Type: OTHER

Princess Filler Lidocaine

Intervention Type: DEVICE

correction of nasolabial folds

Interventions

Princess Filler Lidocaine

correction of nasolabial folds

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects, 22 years of age or older, at the Screening visit

2. Subjects with two fully visible, approximately symmetrical moderate to severe NLFs (same severity) with severity scores of 2 or 3 on the 5- point NLF-SRS for both NLF as judged by the treating investigator in conjunction with the independent blinded evaluating investigator.

3. Females of childbearing potential must have a negative urine pregnancy test at injection visits and must agree to use an adequate method of contraception for the duration of the clinical investigation

4. Healthy skin in the nasolabial area and free of diseases that could interfere in cutaneous aging evaluation

5. Willingness to abstain from any aesthetic or surgical procedures in the treatment area for the duration of the clinical investigation, including botulinum toxin injections (except glabellar or forehead botulinum toxin treatment)

6. Subjects having understood the purpose and conduct of the clinical investigation and having given written informed consent

1. In the opinion of the treating investigator, the subject has returned to sufficient severity of both NLFs that would have qualified him for enrollment into the clinical investigation initially (note that the subject does not have to return to his Baseline severity to be permitted to receive a repeat treatment)

2. Subjects with NLFs with severity scores of 2 or 3 on the 5-point NLF-SRS for both NLFs as judged by the treating investigator in conjunction with the independent blinded evaluating investigator (note that it is not necessary for the treating and evaluating investigator to agree on the same rating)

3. Females of childbearing age must have a negative urine pregnancy test at the repeat-treatment visit and must agree to continue to use an adequate method of contraception for the duration of the clinical investigation

4. Healthy skin in the nasolabial area and free of diseases that could interfere in cutaneous aging evaluation and/or injection

Exclusion Criteria

1. For females: pregnant and/or lactating or planning to become pregnant during the clinical investigation

2. History of allergies or hypersensitivity to HA preparations, lidocaine or anesthetics of any amide-based anesthetic

3. Since Juvéderm® Ultra XC contains trace amounts of Gram-positive bacterial proteins, subjects with history of allergies to such material can not be included in this clinical investigation

4. Tendency to keloid formation, hypertrophic scars and/or pigmentation disorders

5. Known human immune deficiency virus-positive individuals

6. Presence of infectious, inflammatory or proliferative cancerous or pre-cancerous lesions in the area to be treated

7. Re-current herpes simplex in the treatment area

8. History or presence of any autoimmune or connective tissue disease, or current treatment with immunomodulating therapy

9. Uncontrolled (or instable) diabetes mellitus or systemic diseases

10. Facial plastic surgery, tissue augmentation with silicone, fat or another non-absorbable substance (permanent fillers) area of device application

11. Implantation of facial dermal fillers in the treatment area in the preceding twelve months

12. Skin of the nasolabial region affected by aesthetic treatments (e.g. laser therapy, absorbable and non-absorbable sutures (threads), microneedling and/or botulinum toxin within the last twelve months, dermabrasion and mesotherapy within the last six months, chemical peeling within the last three months) or planning to undergo such procedures during the clinical investigation

13. Facial lypolysis, including submental fat treatments, within last month prior to enrollment and during the clinical investigation

14. Bariatric surgery within 12 months prior to enrollement and during the clinical investigation

15. History of bleeding disorders and/or use of anticoagulant, antiplatelet or thrombolytic medication from ten days pre- to three days post injection

16. Planned dental/oral surgery or modification (bridge-work, implants) within two weeks prior injection and to a minimum of four weeks post injection

17. Any medical condition prohibiting the inclusion in the clinical investigation according to the judgment of the treating investigator

18. Previous enrollment in this clinical investigation

19. Current participation in another clinical investigation, or treatment with any investigational drug/medical device within 30 days prior to clinical investigation enrollment

20. Any dependency of the subject to the treating investigator, the blinded independent evaluating investigator or clinical investigation site (e.g. employees of the sponsor), or subjects who are employees or relatives of the treating investigator and/or the independent blinded evaluating investigator

21. Subjects who have one of the following assessments during the visual examinations at Baseline:

Snellen visual acuity test worse than 20/40 (with corrective eyewear, if applicable), abnormal confrontational visual field test, or abnormal ocular motility test.

1. Occurrence of an SAE or adverse event of special interest (AESI; i.e., changes in vision [loss of vision, blurriness, double vision, pain in or around the eye, blindness, blind spots, problems moving the eyes, change in peripheral vision], skin changing color around the eyelids or around the site of injection) during or after the initial injection and/or touch-up injection

2. Subjects who experienced visual changes or other serious medical conditions during or after the initial/touch-up injection

3. Subjects who have one of the following assessments during the visual examinations:

• Snellen acuity test worse than 20/40 (with corrective eyewear, if applicable)
• abnormal confrontational visual field test
• abnormal ocular motility test

4. Subjects who became pregnant since start of the study or are planning to become pregnant during the clinical investigation

5. Known human immune deficiency virus-positive individuals

6. Presence of infectious, inflammatory or proliferative cancerous or pre-cancerous lesions in the area to be treated

7. Development of recurrent herpes simplex in the treatment area since study start

8. Development of any autoimmune or connective tissue disease since start of participation in the study, or current treatment with immunomodulating therapy

9. Development of uncontrolled (or instable) diabetes mellitus or any other systemic disease since study start

10. Development of a bleeding disorder since study start or use of anticoagulant, antiplatelet or thrombolytic medication from ten days pre- to three days post injection

11. Planned dental/oral surgery or modification (bridge-work, implants) within 2 weeks prior to injection and to a minimum of four weeks post injection

12. Any medical condition prohibiting the inclusion for repeat treatment according to the judgement of the treating investigator

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Syneos Health

OTHER

Sponsor Role: collaborator

Croma-Pharma GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Bank, MD

Role: PRINCIPAL_INVESTIGATOR

Center of Dermatology, Cosmetic and Laser Surgery

Joel Cohen, MD

Role: PRINCIPAL_INVESTIGATOR

AboutSkin research, LLC

John Joseph, MDE

Role: PRINCIPAL_INVESTIGATOR

Dr. John Joseph Facial Plastic and Reconstructive Surgery

Gary Monheit, MD

Role: PRINCIPAL_INVESTIGATOR

Total Skin and Beauty Dermatology Center

Ava Shamban, MD

Role: PRINCIPAL_INVESTIGATOR

Ava MD

Susan Taylor, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Robert Weiss, MD

Role: PRINCIPAL_INVESTIGATOR

Maryland Laser Skin and Vein

Sabrina Fabi, MD

Role: PRINCIPAL_INVESTIGATOR

Cosmetic, Lazer, Dermatology

Jeanine Downie, MD

Role: PRINCIPAL_INVESTIGATOR

Image Dermatology P.C.

Jeremy Green, MD

Role: PRINCIPAL_INVESTIGATOR

Skin Research Institute

Michael Gold, MD

Role: PRINCIPAL_INVESTIGATOR

Tennesse Clinical Research Institute

Locations

Gary Monheit

Birmingham, Alabama, United States

John Joseph

Beverly Hills, California, United States

Sabrina Fabi

San Diego, California, United States

Ava Shamban

Santa Monica, California, United States

Joel Cohen

Greenwood Village, Colorado, United States

Jeremy Green

Coral Gables, Florida, United States

Robert Weiss

Hunt Valley, Maryland, United States

Jeanine Downie

Montclair, New Jersey, United States

The Center for Dermatology Cosmetic and Laser Surgery

New York, New York, United States

Susan Taylor

Philadelphia, Pennsylvania, United States

Michael Gold

Nashville, Tennessee, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CPH 301-201200F

Identifier Type: -

Identifier Source: org_study_id